Purpose: Fibroblast growth factor (FGF) 23 is currently recognized to be involved in the occurrence and development of metabolic diseases. The present study aimed to investigate the association between serum FGF23 levels and hepatic steatosis, as well as the influence of sleep duration.
Patients and Methods: The present study population was selected from patients with diagnosed diabetes hospitalized during February 2018 to April 2019. Serum FGF23 levels were assessed by two-side sandwich enzyme-linked immunosorbent assay. The presence and severity of hepatic steatosis were determined by controlled attenuation parameter (CAP). Hepatic steatosis was determined as CAP≥ 302 dB/m.
Results: Serum FGF23 levels were significantly higher in individuals with hepatic steatosis than in those without hepatic steatosis (P =0.004). The present study population was divided into Q1–Q4 according to serum FGF23 quartiles. The risks of hepatic steatosis were increased more than 3 folds in Q2–Q4 (all P < 0.01) compared to Q1. CAP showed an uptrend from Q1 to Q4 (P =0.005), even after adjustment for gender and age (P =0.001). Multivariate variance analyses showed significant differences in CAP among Q1–Q4 (P =0.008) and between individuals with short and long sleep duration (P =0.023), which were independent of each other. Serum FGF23 levels were positively associated with CAP independent of gender, age, total metabolic traits, and sleep duration (P =0.042).
Conclusion: Serum FGF23 levels were independently and positively associated with the severity of hepatic steatosis. The associations of serum FGF23 levels and sleep duration with hepatic steatosis were independent of each other.
Keywords: fibroblast growth factor 23, hepatic steatosis, controlled attenuation parameter, sleep duration